

### Supplementary 1. Literature Search Strategy and Selection Criteria for Subjects

Blood	
#	Search Terms
1	Alzheimer's disease or mild cognitive impairment
2	peripheral or blood or plasma or plasm or serum or sera
3	inflammation or cytokine or chemokine or interferon or interleukin or transforming growth factor or tumor necrosis factor or C-reactive protein
4	1# and 2# and 3#
CSF	
#	Search Terms
1	Alzheimer's disease or mild cognitive impairment
2	cerebrospinal fluid or CSF
3	inflammation or cytokine or chemokine or interferon or interleukin
4	IL-1 $\beta$ or IL-2 or IL-4 or IL-6 or IL-8 or IL-10 or IL-12 or IL-18 or IL-15 or IL-12/23 p40
5	IL-1 receptor agonist or IL-1ra
6	sIL-1R type II or IL-1 receptor type II
7	sIL-6R or soluble IL-6 receptor
8	transforming growth factor or TGF
9	tumor necrosis factor or TNF
10	C-reactive protein or CRP
11	TGF- $\beta$ or transforming growth factor
12	IFN- $\gamma$ or interferon
13	TNF- $\alpha$ or tumor necrosis factor
14	Macrophage colony stimulating factor or M-CSF

15	granulocyte-colony stimulating factor or G-CSF
16	granulocyte macrophage colony stimulating factor or GM-CSF
17	TREM or sTREM or TREM2 or sTREM2
18	MCP-1 or monocyte chemotactic protein-1
19	TRAIL or fractalkine and tumor necrosis factor-related apoptosis-inducing ligand
20	YKL-40 or Chitinase-3-like protein 1 or CHI3L1
21	HGF or hepatocyte growth factor
22	sTNF-RI or soluble TNF receptors I or sTNF-RII
23	IP-10
24	S100b
25	$\alpha$ 1-ACT or $\alpha$ -1-antichymotrypsin or alpha1-antichymotrypsin
26	CCL2 or chemokine (C-C motif) ligand 2
27	MIP-1 $\beta$
28	3 <sup>#</sup> or 4 <sup>#</sup> or 5 <sup>#</sup> or 6 <sup>#</sup> or 7 <sup>#</sup> or 8 <sup>#</sup> or 9 <sup>#</sup> or 10 <sup>#</sup> or 11 <sup>#</sup> or 12 <sup>#</sup> or 13 <sup>#</sup> or 14 <sup>#</sup> or 15 <sup>#</sup> or 16 <sup>#</sup> or 17 <sup>#</sup> or 18 <sup>#</sup> or 19 <sup>#</sup> or 20 <sup>#</sup> or 21 <sup>#</sup> or 22 <sup>#</sup> or 23 <sup>#</sup> or 24 <sup>#</sup> or 25 <sup>#</sup> or 26 <sup>#</sup> or 27 <sup>#</sup>
29	1 <sup>#</sup> and 2 <sup>#</sup> and 28 <sup>#</sup>

### **Selection Criteria for Subjects**

AD and MCI subjects were selected in accordance with the NINCDS-ADRDA criteria, the Petersen rating criteria and other acceptable principles. Controls in peripheral comparisons included cognitive healthy subjects (spouses, volunteers or individuals who were sampled in hospital) without any other neurological disorders and other neuroinflammatory diseases. Because there are clinical restrictions on implementation of lumbar puncture, the number of available studies for CSF markers is limited. Thus, the eligible controls in the CSF research were defined as cognitively normal subjects without inflammatory diseases of central nervous system.